证券代码：688443 证券简称：智翔金泰 公告编号：2025-023 重庆智翔金泰生物制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2024 15 日~2025 10 | 10 | 月 | 年 | 月 | 日 14 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | 回购用途 | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 796,100股 | | | | | | | 累计已回购股数占总股本比例 | 0.2171% | | | | | | | 累计已回购金额 | 20,297,339. ...

Company Overview - Zhixiang Jintai (688443) closed at 29.74 yuan on May 30, 2025, up 7.75% from 27.6 yuan the previous week, with a total market capitalization of 10.905 billion yuan, ranking 24th in the biopharmaceutical sector and 1422nd in the A-share market [1] Key Developments - The company is actively preparing for national medical insurance negotiations for the monoclonal antibody injection, Geniuxi, aiming for early inclusion in the insurance scheme to benefit more patients [1][4] - The GR1802 injection for moderate to severe atopic dermatitis is expected to complete its Phase III clinical trial enrollment by August 2024, currently in the Phase III trial stage [1][2] - The company has established a commercial team of approximately 200 people to promote the commercialization of Geniuxi [2][4] Product Pipeline - The company has two indications for Geniuxi approved for market, while GR1801 and GR2001 injection applications have been accepted, and GR1802 is in Phase III trials for three indications [2][3] - The GR2001 injection new drug application was accepted in May 2025 and is currently awaiting review [3] Strategic Focus - The company is focusing on strategic collaborations with leading domestic distributors and platforms to quickly achieve market coverage and penetration for its products [2] - The company plans to maintain high expenditure levels to support the advancement of its product pipeline and ensure a competitive edge in the market [3] Industry Context - The biopharmaceutical industry is characterized by high investment, high technology, high risk, and long cycles, requiring sustained investment over many years to achieve profitability [2] - The industry is experiencing accelerated high-quality development, driven by favorable policies and increased R&D investments, leading to innovative drug development that addresses unmet clinical needs [3]

Group 1 - The innovative pharmaceutical ETF (560900) has seen a 2.20% increase as of May 29, 2025, with significant trading volume [1] - The CSI Innovative Pharmaceutical Industry Index (931152) rose by 2.32%, with notable gains from constituent stocks such as Zhixiang Jintai (688443) up 8.91%, Sangfor Technologies (688336) up 7.41%, and Maiwei Biotech (688062) up 5.78% [1] - Over the past two weeks, the innovative pharmaceutical ETF (560900) has accumulated a 3.94% increase, ranking it among the top comparable funds [2] Group 2 - CITIC Securities believes that leading innovative pharmaceutical companies have entered a profit phase, with potential for nonlinear profit explosions as commercialization expands [2] - The investment opportunities in the innovative pharmaceutical sector are linked to the clinical progress of molecules under research and the entire commercialization phase, which can last up to ten years [2] - The innovative pharmaceutical ETF closely tracks the CSI Innovative Pharmaceutical Industry Index, which selects no more than 50 representative listed companies involved in innovative drug research and development [2] Group 3 - Morgan Asset Management is integrating its "Global Vision Investment Technology" product line to help investors capitalize on quality technology companies amid a new wave of AI-driven technological advancements [2] - Various actively managed funds focus on emerging industry trends, including the Morgan Emerging Power Fund and the Morgan Smart Connectivity Fund, which targets opportunities in artificial intelligence [3] - The Morgan Hang Seng Technology ETF (513890) and the Morgan CSI Innovative Pharmaceutical Industry ETF (560900) provide passive investment options for technology and innovative pharmaceutical sectors, respectively [3]

证券代码：688443 证券简称：智翔金泰 公告编号：2025-022 重庆智翔金泰生物制药股份有限公司 自愿披露关于GR2001注射液新药上市申请 获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）的 GR2001 注射液用于破伤风的被动免疫适应症的 III 期临床试验达到了主要疗效终点，公 司向国家药品监督管理局（NMPA）药品审评中心（CDE）提交了新药上市申请 并获得受理。 一、药品基本信息 申请人：重庆智翔金泰生物制药股份有限公司 受理号：CXSS2500051 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、药品其他相关情况 GR2001 注射液是一款公司自主研发的重组人源化抗破伤风毒素（Tetanus Neurotoxin, TeNT）的单克隆抗体，注册分类为治疗用生物制品 1 类，作用靶点 为 TeNT 的重链 C 端（TeNT-Hc）。该产品可通过特异性结合 TeNT-Hc，阻断其 进入神经元细胞 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-021 会议召开地点：价值在线（www.ir-online.cn） 重庆智翔金泰生物制药股份有限公司 关于召开2024年年度及2025年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日在上海证券交易所网站（www.sse.com.cn）披露了《2024 年年度报告》 《2024 年年度报告摘要》及《2025 年第一季度报告》。为便于广大投资者更加全 面深入地了解公司经营业绩、发展战略等情况，公司定于 2025 年 5 月 27 日（星 期二）15:00-16:00 在"价值在线"（www.ir-online.cn）举办重庆智翔金泰生物制药 会议召开时间：2025 年 5 月 27 日（星期二）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 ...

| ○ 基金经理:赵蓓 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 累计任职时间：10年又178天 任职起始日期：2014-11-18 | 现任基金公司:工银瑞信基金管理有限公司 | | 基金经理简介:赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加 入工银瑞信.现任研究部副总监、医疗保健研究团队负责人、2014年11月18日至今.担任工银医 疗保健行业股票型基金基金经理:2015年4月28日至今,担任工银瑞信养老产业股票型基金基金 经理;2016年2月3日至今,担任工银瑞信前沿医疗股票型基金基金经理。2018年7月30日至 | | | | | | | 现任基金资产 总规模 | 在管基金最佳 任期回报 | | 2019年12月23日起担任工银瑞信医药健康行业股票型证券投资基金基金经理。2020年05月 | | | | | | | 162.31亿元 | 184.80% | | 20日至2022年6月14日担任工银瑞信科技创新6个月定期开放混合型证券投资基金基金经理, | | ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-020 重庆智翔金泰生物制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 2,000万元~4,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 796,100股 | | 累计已回购股数占总股本比例 | 0.2171% | | 累计已回购金额 | 20,297,339.45元 | | 实际回购价格区间 | 22.89元/股~29.43元/股 | 一、回购股份的基本情况 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）于 2024 年 10 月 15 日召开第一届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购 ...

Core Viewpoint - The recent financial report of Zhixiang Jintai (688443) shows significant revenue growth and improvements in profitability metrics, despite a negative net profit, indicating potential recovery and investment opportunities in the company [1] Financial Performance - The total revenue for Q1 2025 reached 20.16 million yuan, a staggering increase of 318,303.78% year-on-year [1] - The net profit attributable to shareholders was -121 million yuan, reflecting a year-on-year increase of 26.29% [1] - Gross margin improved to 82.93%, up 26.51% year-on-year, while net margin showed a significant increase of 99.98% despite remaining negative at -598.95% [1] Cost and Expenses - Total selling, administrative, and financial expenses amounted to 58.01 million yuan, representing 287.78% of revenue, a decrease of 99.95% year-on-year [1] - The company reported a decrease in cash and cash equivalents to 1.69 billion yuan, down 38.68% from the previous year [1] Shareholder Metrics - The earnings per share (EPS) was -0.33 yuan, an improvement of 26.67% year-on-year [1] - The net asset value per share decreased to 5.46 yuan, down 24.75% year-on-year [1] Fund Holdings - The largest fund holding Zhixiang Jintai is the Dongfanghong Medical Upgrade Stock Fund, which increased its position to 2.54 million shares [4] - Other funds such as the ICBC Medical Health Stock Fund also increased their holdings, indicating positive sentiment among institutional investors [4]

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. reported significant revenue growth in 2024, primarily due to the commercialization of its innovative drug, but still faced substantial net losses [1][2]. Group 1: Financial Performance - The company's operating revenue for 2024 reached 30.09 million yuan, representing a year-on-year increase of 2384.1% [1]. - The net profit attributable to shareholders was a loss of 797 million yuan, which is a reduction compared to the previous year's loss [1]. - In the first quarter of 2024, the company reported an operating revenue of 20.16 million yuan and a net loss of 121 million yuan, indicating a decrease in losses [2]. Group 2: Product Development and Commercialization - The revenue growth was mainly driven by the approval and commercialization of the drug "Jinlixi" (Secukinumab), which is the first fully human anti-IL-17A monoclonal antibody approved in China [1]. - The company maintained high research and development (R&D) investment, with R&D expenses around 610 million yuan in 2024 and a cumulative investment of 1.685 billion yuan over the past three years [2]. - The company is advancing multiple projects into clinical research stages and has established a commercial sales team, indicating a focus on expanding its product pipeline and market presence [2].

重庆智翔金泰生物制药股份有限公司 独立董事 2024 年度述职报告 作为重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"） 第二届董事会的独立董事，本人严格依据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司独立董事管理办法》等法律法规、规章制度，以及《重 庆智翔金泰生物制药股份有限公司章程》（以下简称"《公司章程》"）《独立董事 工作制度》等相关要求，始终秉持客观、公正、独立的核心原则，深度发挥自身 专业特长。审慎行使独立董事权利，积极出席公司董事会，参与公司各项重大决 策，针对相关议题及时发表独立且客观的意见，切实维护公司整体利益，重点保 障股东尤其是中小股东的合法权益得以有效实现，尽心履行诚信、勤勉的职责与 义务，为推动公司稳健发展发挥积极作用。 （二）独立性情况说明 任期内，作为公司的独立董事，本人及父母、子女、主要社会关系均不在公 司或其附属企业任职，没有直接或间接持有公司发行的股份；本人配偶于 2024 年 6 月通过二级市场买入公司股票 2,000 股，目前仍持有；本人及配偶、父母、 子女、主要社会关系均不在直接或间接持有公司已发行股份 5%以上的股东或公 司前五名股 ...